Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls

Expert Opinion on Drug Safety

Volumn 13, Issue 1, 2014, Pages 25-43

  Warkentin, Theodore E ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

(activated) partial thromboplastin time (PTT); Confounding; Disseminated intravascular coagulation (DIC); Heparin induced thrombocytopenia (HIT); Hepatic necrosis; International normalized ratio (INR); Limb amputation; Low molecular weight heparin (LMWH); Microvascular thrombosis; Unfractionated heparin (UFH); Warfarin induced venous limb gangrene

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 8; DALTEPARIN; DANAPAROID; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG TREATMENT FAILURE; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIMB AMPUTATION; MICROTHROMBUS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; TREATMENT FAILURE;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG MONITORING; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE;

EID: 84890467615     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.823946     Document Type: Review

References (80)

1. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):141S-59S (Pubitemid 351892966)
2. Rice L, Beiderlinden M, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edition. CRC Press, Boca Raton, FL; 2013. p. 356-87
3. Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edition. CRC Press, Boca Raton, FL; 2013. 388-428
4. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324(26):1865-75
5. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 Suppl):204S-33S (Pubitemid 39297955)
6. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011;9(Suppl 1):105-17
7. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thromb Haemost 2006;96(5):547-52 (Pubitemid 44782532)
8. Takemoto CM, Streiff MB, Shermock KM, et al. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol 2013;139(4):450-6
9. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24S-43S
10. Patriquin C, Crowther M. Antithrombotic agents. In: Kitchens CS, Konkle BA, Kessler CM, editors. Consultative hemostasis and thrombosis. 3rd edition. WB Saunders, Elsevier, Philadelphia, PA; 2013. p. 477-95
11. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012;32(6):546-58
12. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154(1):49-56 (Pubitemid 24018101)
13. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edn. CRC Press, Boca Raton, FL; 2013. p. 24-76
14. Ranucci M, Isgrò G, Cazzaniga A, et al. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999;14(6):437-42 (Pubitemid 29537489)
15. Goyoso JM. 5-Year incidence of thrombocytosis and the effect of heparin dose response and heparin requirements. J Extra Corp Technol 1999;31(4): 184-90
16. Levy JH. Heparin resistance and antithrombin: should it still be called heparin resistance? J Cardiothorac Vasc Anesth 2004;18(2):129-30 (Pubitemid 38506854)
17. Levy JH, Sniecinski RM. Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years? Anesth Analg 2010;111(4):833-5
18. Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010;149(4):613-19
19. Edson VR, Krivit W, White JG. Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967;70(3):463-70
20. Rosborough TK. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes that monitoring with the activated partial thromboplastin time. Pharmacotherapy 1999;19(6):760-6 (Pubitemid 29277977)
21. Guervil DJ, Rosenberg AF, Winterstein AG, et al. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011;45(7-8):861-8
22. Hauser VM, Rozek SL. Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharm 1986;20(12):964-7 (Pubitemid 17227923)
23. Fragmin (dalteparin sodium injection) product monograph, Pfizer Canada Ltd., last revised 19 July 2010
24. Warkentin TE. Coumarin-induced skin necrosis and venous limb gangrene. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, editors. Hemostasis and thrombosis: basic principles and clinical practice. 6th edition. Lippincott Williams &Wilkins, Philadelphia; 2013. p. 1308-17
25. Warkentin TE. Heparin-induced thrombocytopenia: igG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/ anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996;10(4):249-58 (Pubitemid 26354134)
26. Warkentin TE, Greinacher A, Gruel Y, et al. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011;9(12):2498-500
27. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121(4):535-55 (Pubitemid 36645375)
28. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163(20):2518-24 (Pubitemid 37385796)
29. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330-5
30. Linkins LA, Lee DH. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edition. CRC Press, Boca Raton, FL; 2013. p. 110-50
31. Greinacher A, Potzsch B, Amiral J, et al. Heparin-Associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71(2):247-51 (Pubitemid 24047336)
32. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96(1):182-7 (Pubitemid 30456469)
33. Warkentin TE. Drug-induced immune-mediated thrombocytopenia-from purpura to thrombosis. N Engl J Med 2007;356(9):891-3 (Pubitemid 46339907)
34. Greinacher A, Warkentin TE. Heparin-induced thrombocytopenia. In: Aird WC, editor. Endothelial Biomedicine. Cambridge University Press, Cambridge; 2007. p. 1344-51
35. Rauova L, Arepally G, McKenzie SE, et al. Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia. J Thromb Haemost 2009;7(Suppl 1):249-52
36. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101(5):502-7 (Pubitemid 126335970)
37. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005;94(1):132-5 (Pubitemid 40974717)
38. Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: Two distinct but overlapping syndromes. Expert Opin Drug Saf 2009;8(2):129-44
39. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127(9):804-12 (Pubitemid 27465548)
40. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004;164(1):66-70 (Pubitemid 38067390)
41. Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol 1999;62(1):44-8 (Pubitemid 29416711)
42. Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003;348(11):1067-9 (Pubitemid 36302259)
43. Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol/Oncol Clin N Am 2010;24(4):755-75
44. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341(8):586-92 (Pubitemid 29384168)
45. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145(1):24-33
46. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99(1):73-80 (Pubitemid 29035960)
47. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia (HAT) investigators. Circulation 1999;100(6):587-93 (Pubitemid 29379746)
48. Lubenow N, Eichler P, Lietz T, Greinacher A; HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3(11):2428-36 (Pubitemid 41727158)
49. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):340S-80S
50. Refludan Prescribing Information as of October 2002, Berlex Laboratories, Wayne, NJ
51. Hacquard M, de Maistre E, Lecompte T. Lepirudin: is the approved dosing schedule too high? J Thromb Haemost 2005;3:2593-6 (Pubitemid 41727183)
52. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006;108(5):1492-6 (Pubitemid 44316113)
53. Tschudi M, Lammle B, Alberio L. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with patients. Blood 2009;113(11):2402-9
54. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008;99(5):819-29 (Pubitemid 351705298)
55. Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real world issues. Semin Thromb Hemost 2011;37(6):653-63
56. Verhovsek M, Moffat KA, Hayward CPM. Laboratory testing for fibrinogen abnormalities. Am J Hematol 2008;83(12):928-31
57. Warkentin TE, Greinacher A, Craven S, et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005;94(5):958-64 (Pubitemid 41645934)
58. Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program 2011;2011:143-9
59. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43 (Pubitemid 32328395)
60. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163(15):1849-56 (Pubitemid 36960936)
61. Stossel TP, Levy R. Intravascular coagulation associated with pneumococcal bacteremia and symmetrical peripheral gangrene. Arch Intern Med 1970;125(5):876-8
62. Molos MA, Hall JC. Symmetrical peripheral gangrene and disseminated intravascular coagulation. Arch Dermatol 1985;121(8):1057-61 (Pubitemid 15014951)
63. Johansen K, Hansen ST Jr. Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis. Am J Surg 1993;165(5):642-5 (Pubitemid 23278684)
64. Sharma BD, Kabra SR, Gupta B. Symmetrical peripheral gangrene. Trop Doct 2004;34(1):2-4 (Pubitemid 38168061)
65. Hayes MA, Yau EHS, Hinds CJ, Watson JD. Symmetrical peripheral gangrene: association with noradrenaline administration. Intensive Care Med 1992;18(7):433-6 (Pubitemid 23009493)
66. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286(15):1869-78 (Pubitemid 33010239)
67. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4(1):90-7
68. Hoffmann JN, Wiedermann CJ, Juers M, et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006;95(5):850-6
69. Horvatits T, Trauner M, Fuhrmann V. Hypoxic liver injury and cholestasis in critically ill patients. Curr Opin Crit Care 2013;19(2):128-32
70. Henrion J. Hypoxic hepatitis. Liver Int 2012;32(7):1039-52
71. Raurich JM, Perez O, Llompart-Pou JA, et al. Incidence and outcome of ischemic hepatitis complicating septic shock. Hepatol Res 2009;39(7):700-5
72. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JG. A prospective study of the causes of notably raises aspartate aminotransferase of liver origin. Gut 1999;45(1):129-33 (Pubitemid 29301857)
73. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000;109(2):109-13
74. Siegal DM, Cook RJ, Warkentin TE. Acute hepatic necrosis and ischemic limb necrosis. N Engl J Med 2012;367(9):879-81
75. Warkentin TE, Cuker A. Differential diagnosis of heparin-induced thrombocytopenia and scoring systems. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edition. CRC Press, Boca Raton, FL; 2013. p. 77-109
76. Takemitsu T, Wada H, Hatada T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 2011;105(1):40-4
77. Soysal D, C evik C, Saklamaz A, et al. Coagulation disorders secondary to acute liver failure in Amanita phalloides poisoning: a case report. Turk J Gastroenterol 2006;17(3):198-202 (Pubitemid 46568099)
78. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin 2011;27(4):805-23
79. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007;98:234-42
80. Wanat MA, Hart SR, Putney D, et al. Alternative monitoring of argatroban using plasma-diluted thrombin time. Ann Pharmacother 2013;47(4):e18